论文部分内容阅读
目的:探讨Graves病患者131I治疗前后可溶性细胞凋亡相关蛋白Fas(sFas)和促甲状腺激素受体抗体(TRAb)水平的改变及其相关性。方法:采用酶联免疫吸附试验(ELISA)和放射免疫分析法(RIA)分别检测30例GD患者131I治疗前后血清sFas和TRAb水平,并进行相关性分析,20例年龄与性别相匹配的健康者作为正常对照。结果:GD患者血清sFas水平(3.05±1.25 ng/ml)、TRAb水平(40.4±7.59 ng/ml)显著高于对照组(1.69±0.48 ng/ml、7.10±2.62 ng/ml)(P<0.01、P<0.01);131I治疗后,甲状腺功能恢复正常,症状缓解,sFas(2.11±0.89 ng/ml)、TRAb(16.7±5.78 ng/ml)水平明显下降,但仍高于对照组(P<0.05、P<0.01);sFas与TRAb呈正相关(P<0.01)。结论:GD患者体内存在sFas和TRAb异常表达,131I能有效抑制GD患者自身免疫,sFas和TRAb可能可作为GD诊断和疗效观察的良好指标。
Objective: To investigate the changes of soluble Fas (sFas) and thyrotropin receptor antibody (TRAb) in patients with Graves’ disease before and after 131I treatment. Methods: Serum levels of sFas and TRAb in 30 GD patients before and after treatment with 131I were detected by enzyme linked immunosorbent assay (ELISA) and radioimmunoassay (RIA) respectively. Correlation analysis was performed among 20 healthy subjects with age and gender matched As a normal control. Results: Serum levels of sFas in GD patients (3.05 ± 1.25 ng / ml) and TRAb levels (40.4 ± 7.59 ng / ml) were significantly higher than those in control subjects (1.69 ± 0.48 ng / ml, 7.10 ± 2.62 ng / (P <0.01, P <0.01). After 131I treatment, the thyroid function returned to normal and the symptoms were relieved. The levels of sFas in 2.11 ± 0.89 ng / ml and TRAb in 16.7 ± 5.78 ng / ml group were significantly lower than those in control group 0.05, P <0.01). There was a positive correlation between sFas and TRAb (P <0.01). Conclusion: The abnormal expressions of sFas and TRAb exist in GD patients. 131I can effectively inhibit the autoimmunity of GD patients. SFas and TRAb may be good indicators for the diagnosis and curative effect of GD.